Related Experiment Video
Updated: Dec 25, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
New molecular and biochemical insights of doxorubicin-induced hepatotoxicity
Pureti Lakshmi Prasanna1, Kaviyarasi Renu1, Abilash Valsala Gopalakrishnan1
1Department of Biomedical Sciences, School of Biosciences and Technology, VIT, Vellore, Tamil Nadu 632014, India.
Abstract:
Chemotherapeutic antibiotic doxorubicin belongs to the anthracycline class, slaughters not only the cancer cells but also non-cancerous cells even in the non-targeted organs thereby resulting in the toxicity. The liver is primarily involved in the process of detoxification and this mini-review we focused mainly to investigate the molecular mechanisms heading hepatotoxicity caused due to doxorubicin administration. The alterations in the doxorubicin treated liver tissue include vacuolation of hepatocytes, degeneration of hepatocyte cords, bile duct hyperplasia and focal necrosis. About the literature conducted, hepatotoxicity caused by doxorubicin has been explained by estimating the levels of liver serum biomarkers, ROS production, antioxidant enzymes, lipid peroxidation, and mitochondrial dysfunction. The liver serum biomarkers such as ALT and AST, elated levels of free radicals inducing oxidative stress characterized by a surge in Nrf-2, FOXO-1 and HO-1 genes and diminution of anti-oxidant activity characterized by a decline in SOD, GPx, and CAT genes. The augmented levels of SGOT, SGPT, LDH, creatine kinase, direct and total bilirubin levels also reveal the toxicity in the hepatic tissue due to doxorubicin treatment. The molecular insight of hepatotoxicity is mainly due to the production of ROS, ameliorated oxidative stress and inflammation, deteriorated mitochondrial production and functioning, and enhanced apoptosis. Certain substances such as extracts from medicinal plants, natural products, and chemical substances have been shown to produce an alleviating effect against the doxorubicin-induced hepatotoxicity are also discussed.
Insights
Doxorubicin chemotherapy causes liver damage by increasing oxidative stress and inflammation. This review explores molecular mechanisms of doxorubicin-induced hepatotoxicity and potential protective agents.
Area of Science:
- Pharmacology
- Toxicology
- Hepatology
Background:
- Doxorubicin, an anthracycline chemotherapy, causes significant toxicity in non-cancerous tissues.
- The liver, crucial for detoxification, is a primary target for doxorubicin-induced damage (hepatotoxicity).
Purpose of the Study:
- To investigate the molecular mechanisms underlying doxorubicin-induced hepatotoxicity.
- To review factors contributing to liver damage and potential therapeutic interventions.
Main Methods:
- Literature review focusing on molecular mechanisms of doxorubicin hepatotoxicity.
- Analysis of liver serum biomarkers, oxidative stress markers, antioxidant enzyme activity, and mitochondrial function.
Main Results:
- Doxorubicin treatment leads to hepatocyte vacuolation, degeneration, bile duct hyperplasia, and necrosis.
- Elevated liver enzymes (ALT, AST, SGOT, SGPT, LDH), bilirubin, and creatine kinase indicate hepatic damage.
- Increased reactive oxygen species (ROS), oxidative stress (Nrf-2, FOXO-1, HO-1 surge), and inflammation, alongside decreased antioxidant activity (SOD, GPx, CAT), characterize the toxicity.
- Mitochondrial dysfunction and enhanced apoptosis contribute to liver injury.
Conclusions:
- Doxorubicin-induced hepatotoxicity is primarily mediated by ROS production, oxidative stress, inflammation, mitochondrial dysfunction, and apoptosis.
- Medicinal plant extracts, natural products, and chemical agents show potential in alleviating doxorubicin-induced liver damage.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Hepatic Drug Excretion: Influencing Factors
Peroxisomes

